AU3233197A - Formulation and method for treating congestive heart failure - Google Patents

Formulation and method for treating congestive heart failure

Info

Publication number
AU3233197A
AU3233197A AU32331/97A AU3233197A AU3233197A AU 3233197 A AU3233197 A AU 3233197A AU 32331/97 A AU32331/97 A AU 32331/97A AU 3233197 A AU3233197 A AU 3233197A AU 3233197 A AU3233197 A AU 3233197A
Authority
AU
Australia
Prior art keywords
formulation
moxonidine
dosage form
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32331/97A
Other languages
English (en)
Inventor
John L. McNay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU3233197A publication Critical patent/AU3233197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU32331/97A 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure Abandoned AU3233197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
US08659463 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (1)

Publication Number Publication Date
AU3233197A true AU3233197A (en) 1998-01-05

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32331/97A Abandoned AU3233197A (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Country Status (17)

Country Link
EP (1) EP0914128A1 (cs)
JP (1) JP2000511906A (cs)
KR (1) KR20000016406A (cs)
CN (1) CN1226166A (cs)
AU (1) AU3233197A (cs)
BR (1) BR9709546A (cs)
CA (1) CA2256720A1 (cs)
CZ (1) CZ397698A3 (cs)
EA (1) EA199900006A1 (cs)
HU (1) HUP0003885A2 (cs)
IL (1) IL126966A0 (cs)
NO (1) NO985695L (cs)
PL (1) PL330637A1 (cs)
TR (1) TR199802496T2 (cs)
WO (1) WO1997046241A1 (cs)
YU (1) YU55998A (cs)
ZA (1) ZA974978B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
UA67822C2 (uk) * 1999-02-01 2004-07-15 Солвей Фармас'Ютікалс Гмбх Моксонідин для лікування зумовлених інфарктом міокарда уражень серцевого м'яза, спосіб одержання фармацевтичної композиції
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
HUP0003885A2 (hu) 2001-04-28
NO985695L (no) 1999-02-04
CN1226166A (zh) 1999-08-18
KR20000016406A (ko) 2000-03-25
PL330637A1 (en) 1999-05-24
IL126966A0 (en) 1999-09-22
CZ397698A3 (cs) 1999-05-12
CA2256720A1 (en) 1997-12-11
ZA974978B (en) 1998-12-07
NO985695D0 (no) 1998-12-04
WO1997046241A1 (en) 1997-12-11
EP0914128A1 (en) 1999-05-12
YU55998A (en) 1999-11-22
EA199900006A1 (ru) 1999-06-24
BR9709546A (pt) 1999-08-10
TR199802496T2 (xx) 1999-02-22
JP2000511906A (ja) 2000-09-12

Similar Documents

Publication Publication Date Title
JP5666087B2 (ja) Ｃｎｓ関連疾患の治療のための方法及び組成物
US8362085B2 (en) Method for administering an NMDA receptor antagonist to a subject
KR940000100B1 (ko) 메토프롤롤염을 함유하는 서방형 제제의 제조방법
US20170112767A1 (en) Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EA002720B1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
EP0948320B1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN
JP2009173669A (ja) 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
PL186745B1 (pl) Preparat farmaceutyczny zawierający inhibitor ACE, ramipryl i związek dihydropirydynowy
JP2000507613A (ja) Ｄｆｍｏ含有持続放出配合物
BRPI0610634A2 (pt) combinação para a terapia de hiperplasia benigna da próstata
TW201138775A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US9713592B2 (en) Matrix-based pulse release pharmaceutical formulation
AU3233197A (en) Formulation and method for treating congestive heart failure
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
ZA200401547B (en) A new extended release oral dosage form.
MXPA98010056A (en) Formulation and method for dealing with insufficienciacardiac, congest
PL227900B1 (pl) Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
KR20190001340A (ko) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
JP2009539990A (ja) Ｃｘｃｒ２またはｃｘｃｒ１とｃｘｃｒ２との両方のいずれかの選択的アンタゴニストの薬学的処方物および組成物ならびに炎症性障害を治療するためにそれらを使用する方法
KR20190107838A (ko) 이바브라딘의 서방성 약제학적 조성물 및 이의 제조방법
WO2024109927A1 (zh) 包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用
WO2003057198A1 (fr) Compositions pharmaceutiques a liberation modifiee
KR20240014345A (ko) 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법
EP3893852A1 (en) Solid oral pharmaceutical compositions for chronotropic administration of sartans
WO2019161209A1 (en) Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses